Clinical Trials Directory

Trials / Unknown

UnknownNCT05012189

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Comparative Effectiveness of Baloxavir Versus Oseltamivir for Influenza Outbreak Management in U.S. Nursing Homes

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
1,000 (estimated)
Sponsor
Insight Therapeutics, LLC · Academic / Other
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Accepted

Summary

Influenza outbreaks are a prevalent event in nursing homes (NHs). We will study baloxavir compared to oseltamivir when used for influenza prophylaxis when facilities identify an index incident case of influenza. This study will help guide nursing home's decision making and demonstrate the effectiveness of a novel antiviral for preventing influenza outbreaks.

Detailed description

A random study sample of about 1000 U.S. nursing homes (NHs), housing approximately 112,000 overall residents and 92,000 over the age of 65 years, of whom 64,500 are long-stay NH residents, will be recruited for the study. Participating facilities will be randomly allocated in a 1:1 ratio to oseltamivir or baloxavir for antiviral treatment and prophylaxis. Primary study data provided by facilities monthly during the influenza season will support primary and secondary endpoints along with administrative claims and public use datasets containing information on facility characteristics.

Conditions

Interventions

TypeNameDescription
DRUGOseltamivirNursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.
DRUGBaloxavirNursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.

Timeline

Start date
2021-08-06
Primary completion
2023-12-01
Completion
2023-12-01
First posted
2021-08-19
Last updated
2023-03-15

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05012189. Inclusion in this directory is not an endorsement.